Drug Profile
Amikacin inhalation - Nektar Therapeutics
Alternative Names: Aerosolised amikacin; Amikacin inhale; BAY-416551; Inhaled amikacin; NKTR-061Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nektar Therapeutics
- Developer Bayer HealthCare; Nektar Therapeutics
- Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Gram-negative infections; Ventilator associated pneumonia
Most Recent Events
- 13 Jan 2018 Bayer terminates its licence for inhaled amikacin
- 07 Apr 2017 Bayer completes the phase III INHALE 2 trial in Gram-negative infections and Ventilator-associated-pneumonia in Belgium, China, France, Germany, Greece, Hungary, Israel, Italy, Japan, the Netherlands, Poland, Portugal, Russia, Spain, Ukraine, Czech Republic, Latvia (NCT00805168)
- 06 Apr 2017 Bayer completes the phase III INHALE 1 trial in Gram-negative infections and Ventilator-associated-pneumonia in USA, Argentina, Australia, Brazil, Canada, Colombia, Czech Republic, South Korea, Mexico, Philippines, Taiwan, Thailand, Turkey (NCT01799993)